XERS

Xeris Biopharma Holdings Stock Analysis

AI Rating

Neutral
  • Quality2/10
  • Growth↑ 8/10
  • Value↓ 2/10
Xeris Biopharma Holdings sales and earnings growth
XERS Growth
Good
  • Revenue Y/Y↑ 41.47%
  • EPS Y/Y↑ 123.33%
  • FCF Y/Y↑ 273.26%
Xeris Biopharma Holdings gross and profit margin trends
XERS Profitability
Good
  • Gross margin ↑ 85.90%
  • EPS margin↓ 3.80%
  • ROIC 5Y↓ -6.23%
Xeris Biopharma Holdings net debt vs free cash flow
XERS Risk
Poor
  • Debt / Equity↑ 19.9
  • Debt / FCF↓ 3.1
  • Interest coverage↓ 1.4

Xeris Biopharma Holdings stock is less volatile than the overall market, so it's low risk. We give it a Poor risk rating.

↗ More Biotechnology stocks